MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration

C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso (Móstoles, Spain)

Meeting: 2023 International Congress

Abstract Number: 55

Keywords: Magnetic resonance imaging(MRI), Parkinson’s, Positron emission tomography(PET)

Category: Parkinson’s Disease: Clinical Trials

Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra (SN) in Parkinson´s disease (PD) patients.

Background: The BBB is a major limiting factor for brain delivery of therapeutic investigational agents. The nigrostriatal system is especially vulnerable to neurodegeneration in PD. MRgFUS in combination with intravenous microbubble administration leads to focal temporary BBB-O. We have shown that striatal BBB-O of the parietal cortex and the putamen is viable in PD with cognitive impairment (Gasca-Salas et al, 2021; Pineda-Pardo et al 2022).

Method: Safety and feasibility study of BBB-O of the SN in PD (NCT03608553 trial). Patients underwent clinical evaluations and brain MR imaging with gadolinium at baseline, 24 hours, 14 days, and 3 months post-procedure. Gadolinium uptake is standardized  test for BBB-O. Three PD patients underwent MRgFUS for midbrain and putamen BBB-O. In two patients the procedure was repeated twice 3 weeks apart. In 2 patients 18F-Choline PET was performed immediately after BBB-O.

Results: The right SN was opened in 4 sessions in 3 patients, and the left SN in one patient once only.  The right SN and putamen were simultaneously opened unilaterally in 2 patients. No clinical or neuroimaging adverse events developed immediately or subsequently in any patient. 18F-Choline PET uptake in the midbrain SN region and the putamen was clearly enhanced precisely and exclusively in the targeted regions.

Conclusion: These findings indicate that nigrostriatal BBB opening of the nigro-striatal system by low intensity MRgFUS in PD is a feasible and well-tolerated approach.  18F-Choline PET reveals cell membrane binding, indirectly indicating penetration into the parenchyma after BBB-O. This minimally invasive technique could effectively facilitate delivery of putative neurorestorative molecules to brain regions vulnerable to neurodegeneration.

To cite this abstract in AMA style:

C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso. Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/substantia-nigra-blood-brain-barrier-opening-in-parkinsons-disease-pet-18f-choline-evidence-of-parenchymal-penetration/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/substantia-nigra-blood-brain-barrier-opening-in-parkinsons-disease-pet-18f-choline-evidence-of-parenchymal-penetration/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley